Search
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationala short peptide linker. … Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalAs such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients … hemophilia A [F3649].
Cefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnCefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate].
Diloxanide
go.drugbank.com/drugs/DB08792ExperimentalDiloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. … Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigationaltarget VEGF-A. … [A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely
Basiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalA recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … known as CD25 antigen) on the surface of activated T-lymphocytes.
Colfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawnColfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.
EHC18
go.drugbank.com/drugs/DB05114ExperimentalEHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.